Skip to main content
LYSOGENE logo

LYSOGENE — Investor Relations & Filings

Ticker · LYS ISIN · FR0013233475 LEI · 969500T64RILK1RD0852 PA Professional, scientific and technical activities
Open in API
Filings indexed 254 across all filing types
Latest filing 2021-07-05 Capital/Financing Update
Country FR France
Listing PA LYS

About LYSOGENE

https://www.lysogene.com

Lysogene was a clinical-stage biotechnology company that specialized in the research and development of gene therapies for rare, inherited neurodegenerative diseases affecting the central nervous system (CNS). The company's approach focused on delivering a functional copy of a deficient gene directly to the brain to address the root cause of the targeted disorder. Its pipeline included investigational treatments for lysosomal storage diseases such as Sanfilippo syndrome type A (MPS IIIA) and GM1 gangliosidosis. Following clinical and financial challenges, the company initiated judicial liquidation proceedings in 2023.

Recent filings

Filing Released Lang Actions
Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Capital/Financing Update Classification · 1% confidence The document is explicitly titled 'Half-year liquidity contract statement for LYSOGENE' and details the activity (shares held, cash balance, number of buy/sell executions, and traded volumes) under a liquidity contract with Kepler Cheuvreux as of June 30th, 2021, comparing it to the previous statement on December 31st, 2020. This type of regular disclosure regarding share trading activities under a market-making or liquidity agreement, often mandated by regulators like the AMF (mentioned in the text), is a specific type of corporate action disclosure. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR). It most closely relates to ongoing capital/financing activities or regulatory disclosures. Since it is a specific report on a liquidity contract, it is a specialized disclosure. Given the options, it doesn't fit perfectly into the standard financial reports (10-K, IR, ER) or management/board changes. It is a report detailing specific financial/market operations. While it could potentially fall under RNS (Regulatory Filings) as a fallback, the content is highly specific to share trading/liquidity management. However, none of the provided codes explicitly cover 'Liquidity Contract Statement' or 'Share Trading Activity Report' outside of 'Transaction in Own Shares' (POS), which usually refers to formal buybacks/issuance by the company itself, not third-party liquidity provision. Given the context of regular, periodic reporting on share transactions and cash balances related to market stability, and lacking a better fit, it is best classified as a specific regulatory disclosure. Since it details transactions and capital management, and is not a standard financial statement, it is most appropriately categorized as a specialized regulatory filing or a capital/financing update. Because it is a statement of activity under a contract, and not a general capital change (SHA) or a formal buyback (POS), the most appropriate general category for specific, non-standard regulatory disclosures is RNS, or potentially CAP if viewed as part of financing infrastructure. Given the detailed nature of the report, it is more substantial than a simple RNS announcement, but it is not a core financial report. Reviewing the definitions, 'Transaction in Own Shares' (POS) is about the company buying back shares; this is about a liquidity provider's activity. Therefore, RNS (Regulatory Filings / miscellaneous) is the safest classification for this specific, non-standard report type, unless it is considered a form of capital management disclosure. I will lean towards RNS as the most appropriate catch-all for specific, non-standard periodic reports not covered elsewhere.
2021-07-05 English
Inside Information / Other news releases
AGM Information Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces the results from the "ordinary annual and extraordinary general meeting of shareholders" held on June 25, 2021. It details that shareholders approved all proposed resolutions, including financial statements and compensation policies. This content directly relates to the outcomes and proceedings of an Annual General Meeting (AGM). While it mentions the adoption of the 2020 financial statements (which might suggest a 10-K component), the primary focus and context of the release is the meeting itself and the voting results. The most specific category for materials related to the AGM is 'AGM Information' (AGM-R). It is not a full 10-K, nor is it solely a DVA (Declaration of Voting Results), as it covers more than just the vote tally (e.g., compensation policy approval). Therefore, AGM-R is the best fit.
2021-06-25 English
Informations privilégiées / Autres communiqués
AGM Information Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the results of the company's "Assemblée générale ordinaire annuelle et extraordinaire" (Annual General and Extraordinary Shareholders' Meeting) held on June 25, 2021. It confirms that all resolutions were adopted, including the approval of the 2020 accounts and remuneration policy. This document is an announcement regarding the outcome of a shareholder meeting, specifically detailing the voting results for the resolutions presented. This aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to the AGM, the core content is the voting outcome announcement, not the AGM presentation materials (AGM-R) or the proxy solicitation materials (PSI).
2021-06-25 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces a significant corporate event: entering into an exclusive worldwide license agreement for a gene therapy candidate. It details the terms, the parties involved (Lysogene and SATT Conectus), and includes commentary from management. This type of announcement, which details a major business development (like a licensing deal or partnership) but is not a full financial report (10-K, IR) or a specific regulatory filing like a Director's Dealing (DIRS) or Capital Change (SHA), typically falls under a general corporate announcement category. Since it is a press release detailing a strategic business transaction (licensing), it is best classified as a general Regulatory Filing (RNS) as it is a public disclosure of material information, or potentially a Capital/Financing Update (CAP) if the focus was purely on the financial structure, but the core event is the licensing deal itself. Given the options, RNS serves as the best general category for material, non-standardized corporate news releases that aren't explicitly covered elsewhere. It is not an Earnings Release (ER) as it contains no financial results, nor is it a Call Transcript (CT). It is a standalone announcement, not an announcement *of* a report (RPA).
2021-06-11 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a significant corporate event: Lysogene signing an exclusive worldwide license agreement with SATT Conectus for a gene therapy candidate targeting Fragile X Syndrome. It details the terms, the scientific background, market potential, and includes quotes from management. This type of announcement, focusing on a major business development (licensing deal, partnership, or acquisition), is typically classified as a general corporate announcement or a specific event announcement. Since there is no specific category for 'Licensing Agreement Announcement', and it is not a formal regulatory filing like a 10-K, an Earnings Release (ER), or a Dividend Notice (DIV), it falls best under the general regulatory/corporate announcement category, which is RNS (Regulatory Filings) as the fallback for miscellaneous filings, or potentially a general announcement if one existed. Given the options, RNS is the most appropriate catch-all for significant, non-standard corporate news releases that are not explicitly defined elsewhere. It is not an ER (no financial results), not an IP (it's a press release, not a presentation), and not a CT (it's not a transcript). It is a formal announcement of a transaction, making RNS the best fit among the provided codes.
2021-06-11 French
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Regulatory Filings Classification · 1% confidence The document is titled 'COMMUNIQUE DE PRESSE' (Press Release) and announces a significant operational milestone: the treatment of the first patient in a clinical trial (LYS-GM101 for GM1 gangliosidosis). It provides key highlights, quotes from management and investigators, and details about the trial and the company's pipeline. This structure—a brief announcement focusing on recent operational news rather than comprehensive financial statements (like 10-K or IR) or detailed management analysis (like MDA)—is characteristic of an Earnings Release (ER) or a general press release announcing corporate progress. Since it is not explicitly an earnings announcement but a clinical trial update, and it is not a short notice about a report publication (RPA), the most fitting category for a major operational/clinical update announced via press release is the Earnings Release (ER) category, which often serves as the primary vehicle for significant corporate news outside of mandatory financial filings. Given the context of a clinical trial milestone announcement, ER is the closest fit among the provided options for a major, time-sensitive corporate update.
2021-06-09 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.